Clinical Trial Update: An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR) [Phase 4]

View source ↗

Summary

Phase 4 open-label trial evaluating tapentadol ER in chronic pain patients after conversion from other opioids was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Back Pain
• Low Back Pain
• Osteoarthritis Pain in the Hip or Knee
• Pain

Drugs mentioned

• Tapentadol ER (Tapentadol)

Snippet

Sponsor: Janssen Scientific Affairs, LLC | Conditions: Pain, Chronic Back Pain | Phase 4 | Status: WITHDRAWN